Tempus AI is expanding its partnership with Verastem Oncology to develop a companion diagnostic (CDx) for the latter’s ...

Silexion’s new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional ...

KRAS and NRAS are members of the RAS family of genes, which encode proteins that regulate cell growth and division through ...

The investigational assay prospectively assesses KRAS status in patients with recurrent LGSOC to group patients into KRAS-mutation or KRAS-wild type cohorts for analysis in the primary and ...

“Today’s approval of AVMAPKI FAKZYNJA CO-PACK for patients with KRAS-mutated recurrent low-grade serous ovarian cancer represents not only the first-ever FDA-approved treatment specifically ...

Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though ...

Tempus' FDA-approved xT CDx test is being used as an investigational assay in Verastem's global Phase 3 RAMP-301 clinical trial.

On May 8, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer ...

The Food and Drug Administration (FDA) has granted accelerated approval to Avmapki ™ (avutometinib) plus Fakzynja ™ (defactinib) for the treatment of adult patients with KRAS -mutated recurrent ...